The proper role of β2-adrenergic agonists in the treatment of children with asthma

β-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the β-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increas...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 1992-10, Vol.90 (4), p.639-640
Main Authors: FURUKAWA, C. T, KEMP, J. P, SIMONS, F. E. R, TINKELMAN, D. G
Format: Article
Language:English
Subjects:
Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
Respiratory system
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c179t-c0e375b387e84af23d62e804f038836796432f9970c432685e443efcefa292803
cites
container_end_page 640
container_issue 4
container_start_page 639
container_title Pediatrics (Evanston)
container_volume 90
creator FURUKAWA, C. T
KEMP, J. P
SIMONS, F. E. R
TINKELMAN, D. G
description β-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the β-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increased risk of death with regular use of β-agonists, particularly fenoterol.4 Fenoterol may be uniquely less safe than other β-agonists because of a greater cardiotoxic potential due to less β2 specificity (than terbutaline) and a greater relative dose per actuation.5 The concerns about the safety of β-agonists are linked intimately with the concerns about their effectiveness in asthma therapy.
doi_str_mv 10.1542/peds.90.4.639
format article
fullrecord <record><control><sourceid>pascalfrancis_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1542_peds_90_4_639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4395452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c179t-c0e375b387e84af23d62e804f038836796432f9970c432685e443efcefa292803</originalsourceid><addsrcrecordid>eNo90L1OwzAQwHELgUQpjOweWBMu_ojtEVV8SZUYKHNknHNjlCaRbQnxWjwIz0SiIqa74Xc3_Am5rqCspGC3E7apNFCKsubmhKwqMLoQTMlTsgLgVSEA5Dm5SOkDAIRUbEVedx3SKY4TRhrHHuno6c83K2wbccC4D47a_TiElBMNA82zzhFtPuCQF-u60C-UfobcUZtyd7CX5MzbPuHV31yTt4f73eap2L48Pm_utoWrlMmFA-RKvnOtUAvrGW9rhhqEB641r5WpBWfeGAVuXmotUQiO3qG3zDANfE2K418Xx5Qi-maK4WDjV1NBsxRpliKNgUY0c5HZ3xz9ZJOzvY92cCH9HwlupJCM_wL6JmGN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The proper role of β2-adrenergic agonists in the treatment of children with asthma</title><source>EZB Electronic Journals Library</source><creator>FURUKAWA, C. T ; KEMP, J. P ; SIMONS, F. E. R ; TINKELMAN, D. G</creator><creatorcontrib>FURUKAWA, C. T ; KEMP, J. P ; SIMONS, F. E. R ; TINKELMAN, D. G</creatorcontrib><description>β-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the β-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increased risk of death with regular use of β-agonists, particularly fenoterol.4 Fenoterol may be uniquely less safe than other β-agonists because of a greater cardiotoxic potential due to less β2 specificity (than terbutaline) and a greater relative dose per actuation.5 The concerns about the safety of β-agonists are linked intimately with the concerns about their effectiveness in asthma therapy.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.90.4.639</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: American Academy of Pediatrics</publisher><subject>Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments ; Respiratory system</subject><ispartof>Pediatrics (Evanston), 1992-10, Vol.90 (4), p.639-640</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c179t-c0e375b387e84af23d62e804f038836796432f9970c432685e443efcefa292803</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4395452$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>FURUKAWA, C. T</creatorcontrib><creatorcontrib>KEMP, J. P</creatorcontrib><creatorcontrib>SIMONS, F. E. R</creatorcontrib><creatorcontrib>TINKELMAN, D. G</creatorcontrib><title>The proper role of β2-adrenergic agonists in the treatment of children with asthma</title><title>Pediatrics (Evanston)</title><description>β-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the β-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increased risk of death with regular use of β-agonists, particularly fenoterol.4 Fenoterol may be uniquely less safe than other β-agonists because of a greater cardiotoxic potential due to less β2 specificity (than terbutaline) and a greater relative dose per actuation.5 The concerns about the safety of β-agonists are linked intimately with the concerns about their effectiveness in asthma therapy.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNo90L1OwzAQwHELgUQpjOweWBMu_ojtEVV8SZUYKHNknHNjlCaRbQnxWjwIz0SiIqa74Xc3_Am5rqCspGC3E7apNFCKsubmhKwqMLoQTMlTsgLgVSEA5Dm5SOkDAIRUbEVedx3SKY4TRhrHHuno6c83K2wbccC4D47a_TiElBMNA82zzhFtPuCQF-u60C-UfobcUZtyd7CX5MzbPuHV31yTt4f73eap2L48Pm_utoWrlMmFA-RKvnOtUAvrGW9rhhqEB641r5WpBWfeGAVuXmotUQiO3qG3zDANfE2K418Xx5Qi-maK4WDjV1NBsxRpliKNgUY0c5HZ3xz9ZJOzvY92cCH9HwlupJCM_wL6JmGN</recordid><startdate>19921001</startdate><enddate>19921001</enddate><creator>FURUKAWA, C. T</creator><creator>KEMP, J. P</creator><creator>SIMONS, F. E. R</creator><creator>TINKELMAN, D. G</creator><general>American Academy of Pediatrics</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19921001</creationdate><title>The proper role of β2-adrenergic agonists in the treatment of children with asthma</title><author>FURUKAWA, C. T ; KEMP, J. P ; SIMONS, F. E. R ; TINKELMAN, D. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c179t-c0e375b387e84af23d62e804f038836796432f9970c432685e443efcefa292803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FURUKAWA, C. T</creatorcontrib><creatorcontrib>KEMP, J. P</creatorcontrib><creatorcontrib>SIMONS, F. E. R</creatorcontrib><creatorcontrib>TINKELMAN, D. G</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FURUKAWA, C. T</au><au>KEMP, J. P</au><au>SIMONS, F. E. R</au><au>TINKELMAN, D. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The proper role of β2-adrenergic agonists in the treatment of children with asthma</atitle><jtitle>Pediatrics (Evanston)</jtitle><date>1992-10-01</date><risdate>1992</risdate><volume>90</volume><issue>4</issue><spage>639</spage><epage>640</epage><pages>639-640</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>β-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the β-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increased risk of death with regular use of β-agonists, particularly fenoterol.4 Fenoterol may be uniquely less safe than other β-agonists because of a greater cardiotoxic potential due to less β2 specificity (than terbutaline) and a greater relative dose per actuation.5 The concerns about the safety of β-agonists are linked intimately with the concerns about their effectiveness in asthma therapy.</abstract><cop>Elk Grove Village, IL</cop><pub>American Academy of Pediatrics</pub><doi>10.1542/peds.90.4.639</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 1992-10, Vol.90 (4), p.639-640
issn 0031-4005
1098-4275
language eng
recordid cdi_crossref_primary_10_1542_peds_90_4_639
source EZB Electronic Journals Library
subjects Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
Respiratory system
title The proper role of β2-adrenergic agonists in the treatment of children with asthma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A10%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20proper%20role%20of%20%CE%B22-adrenergic%20agonists%20in%20the%20treatment%20of%20children%20with%20asthma&rft.jtitle=Pediatrics%20(Evanston)&rft.au=FURUKAWA,%20C.%20T&rft.date=1992-10-01&rft.volume=90&rft.issue=4&rft.spage=639&rft.epage=640&rft.pages=639-640&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.90.4.639&rft_dat=%3Cpascalfrancis_cross%3E4395452%3C/pascalfrancis_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c179t-c0e375b387e84af23d62e804f038836796432f9970c432685e443efcefa292803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true